MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
13.72
-0.49
-3.45%
After Hours: 13.72 0 0.00% 16:10 05/15 EDT
OPEN
14.02
PREV CLOSE
14.21
HIGH
14.02
LOW
13.33
VOLUME
181.20K
TURNOVER
--
52 WEEK HIGH
16.33
52 WEEK LOW
3.350
MARKET CAP
512.94M
P/E (TTM)
-7.0283
1D
5D
1M
3M
1Y
5Y
1D
Contineum Therapeutics grants 51,000-share inducement stock option to new employee
PUBT · 19h ago
CONTINEUM THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 19h ago
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 1d ago
Contineum Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16
Benzinga · 1d ago
Contineum Therapeutics to present at RBC Capital Markets Global Healthcare Conference
PUBT · 3d ago
Contineum presents PIPE-791 pulmonary fibrosis data at ATS 2026 conference
PUBT · 4d ago
Weekly Report: what happened at CTNM last week (0504-0508)?
Weekly Report · 5d ago
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.